SRAX - SRAX Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SRAX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRAX shares.
View SRAX analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 12-month target prices for SRAX's shares. Their SRAX share price forecasts range from $6.00 to $13.50. On average, they predict the company's share price to reach $9.75 in the next year. This suggests a possible upside of 470.2% from the stock's current price.
View analysts price targets for SRAX or view top-rated stocks among Wall Street analysts.

SRAX's stock was trading at $4.49 on January 1st, 2022. Since then, SRAX shares have decreased by 61.9% and is now trading at $1.71.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our SRAX earnings forecast.

SRAX, Inc. (NASDAQ:SRAX) released its earnings results on Monday, November, 15th. The business services provider reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.19. The business services provider had revenue of $8.31 million for the quarter, compared to the consensus estimate of $8.25 million. SRAX had a negative net margin of 129.60% and a negative trailing twelve-month return on equity of 55.13%. During the same period in the prior year, the firm posted ($0.17) earnings per share.

Shares of SRAX split on Friday, September 17th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were payable to shareholders after the market closes on Friday, September 17th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

SRAX updated its first quarter 2022 earnings guidance on Monday, July, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.50 million-$11.50 million, compared to the consensus revenue estimate of $11.50 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other SRAX investors own include TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Lowe's Companies (LOW), Block (SQ), Skyworks Solutions (SWKS), TransEnterix (TRXC), Tesla (TSLA), Vuzix (VUZI), Wells Fargo & Company (WFC) and Advanced Micro Devices (AMD).

SRAX trades on the NASDAQ under the ticker symbol "SRAX."

Shares of SRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRAX stock can currently be purchased for approximately $1.71.

SRAX (NASDAQ:SRAX) has a market capitalization of $44.72 million and generates $28.55 million in revenue each year. The business services provider earns $-34,320,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

The company employs 158 workers across the globe.

SRAX's mailing address is 456 SEATON STREET, LOS ANGELES CA, 90013. The official website for the company is www.srax.com. The business services provider can be reached via phone at (323) 694-9800 or via email at srax@lhai.com.